Back to results
US 11,697,851 B2Granted
Early ovarian cancer detection diagnostic test based on mRNA isoforms
AssigneeThe Regents of the University of California
InventorsChristian Barrett, Dennis A. Carson, Kelly Frazer
Life of this patent
Estimating the term…
Abstract
A method to detect ovarian cancer is provided that employs probes and/or primers to detect certain RNA isoform transcripts, as well as kits therefor.
Claims18
A method for detecting the presence of ovarian cancer, comprising:
- (a) obtaining amplified nucleic acid from a cervical or endometrial sample from a human patient, wherein the amplified nucleic acid is obtained using at least one primer having a nucleotide sequence comprising SEQ ID NO:
- 93, SEQ ID NO:94, SEQ ID NO:115, or SEQ ID NO:116, or at least one primer having at least 80% identity thereto;
- (b) measuring in the sample the amount of at least one mRNA isoform of MYLPF having a sequence comprising MYLPF-specific sequences in SEQ ID NO:93 and in the complement of SEQ ID NO:94 and at least one mRNA isoform of LSR having a sequence comprising LSR-specific sequences in SEQ ID NO:115 and in the complement of SEQ ID NO:116;
- and (c) determining whether the amount of the least one mRNA isoform of MYLPF having a sequence comprising MYLPF-specific sequences in SEQ ID NO:93 and in the complement of SEQ ID NO:94 and of the at least one mRNA isoform of LSR having a sequence comprising LSR-specific sequences in SEQ ID NO:115 and in the complement of SEQ ID NO:116 in the sample from the human patient is increased relative to the amount of the at least one mRNA isoform of MYLPF and the at least one mRNA isoform of LSR in a corresponding normal sample, wherein an increased amount of the at least one mRNA isoform of MYLPF and of the at least one mRNA isoform of LSR in the sample from the human patient is indicative of ovarian cancer in the human patient.
1 more element
A method for detecting the presence of ovarian cancer, comprising:
- (a) amplifying nucleic acid from a cervical or endometrial sample from a human patient with a set of primers, wherein one set of primers has a nucleotide sequence comprising SEQ ID NO:
- 93 or a sequence with at least 80% identity thereto, and one comprising SEQ ID NO:94 or a sequence with at least 80% identity thereto, and another set of primers has a nucleotide sequence comprising SEQ ID NO:
- 115 or a sequence with at least 80% identity thereto, and one comprising SEQ ID NO:
- 116 or sequence having at least 80% identity;
- (b) detecting in the sample the presence or the amount of at least one mRNA isoform of MYLPF having a sequence comprising MYLPF-specific sequences in SEQ ID NO:93 and in the complement of SEQ ID NO:94 and at least one mRNA isoform of LSR having a sequence comprising LSR-specific sequences in SEQ ID NO:
- 115 and in the complement of SEQ ID NO:
- 116;
- and
- (c) determining:
- i) whether the amount of the at least one mRNA isoform of MYLPF and the at least one mRNA isoform of LSR in the sample from the human patient is increased relative to the amount of the at least one mRNA isoform of MYLPF and the at least one mRNA isoform of LSR in a corresponding normal sample, wherein an increased amount of the at least one mRNA isoform of MYLPF and of the at least one mRNA isoform of LSR in the sample from the human patient is indicative of ovarian cancer in the human patient, or ii) the presence of the at least one mRNA isoform of MYLPF and the at least one mRNA isoform of LSR in the sample from the human patient relative to the at least one mRNA isoform of MYLPF and the at least one mRNA isoform of LSR in a corresponding normal sample, wherein the presence of the at least one mRNA isoform of MYLPF and of the at least one mRNA isoform of LSR in the sample from the human patient and the absence of the at least one mRNA isoform of MYLPF and the at least one mRNA isoform of LSR in a corresponding normal sample is indicative of ovarian cancer in the human patient.
7 more elements
Dependencies are inferred from the claim text.